The past decade, the therapeutic landscape for metastatic prostate cancer underwent a
massive paradigm shift. Earlier treatment intensification, improved treatment
sequencing, and introduction of new agents have improved the standard-of-care (SOC).
However, when initiating a new line of systemic therapy, drug selection is typically
driven by availability, reimbursement criteria, and clinical judgment. Predictive
biomarkers that can inform which patient could benefit more from the association of e.g.
a cytotoxic versus a new hormonal agent (NHA) is an unmet medical need.
Despite multiple
retrospective studies having identified biomarkers that may have predictive potential,
only a few randomised trials have validated their clinical utility. The Prostate
Biomarker (ProBio) trial hypothesises that biomarker-driven treatment selection will
increase progression-free survival (PFS, primary endpoint), and result in prolonged
overall survival and improved quality-of-life (secondary endpoints).
Sponsor and Coordinating Investigator
Project Coordinator
Project Coordinator
Project Coordinator
Sponsor Genomics
Sponsor Statistics
Post-doctoral Researcher
Post-doctoral Researcher
Biostatistician
Research Engineer
Research Engineer
Bioinformatician
Bioinformatician
Bioinformatician
System Software Developer
January 22, 2024
The right therapy at the right time. It sounds obvious, but every patient is different. In the ProBio research by Dr. Bram De Laere (UGent), men with metastatic prostate cancer are treated based on the tumor profile in their blood.
January 04, 2024
Zachary Klaassen interviews Henrik Grönberg about the ProBio trial, presented at ESMO 2023. The ProBio trial, designed in 2019, is a platform trial aimed at determining the optimal treatment sequence for metastatic prostate cancer and identifying predictive biomarkers for treatment efficacy.
December 05, 2023
Bram De Laere, PhD, Ghent University in Belgium, discusses the ongoing Phase III ProBio (NCT03903835) trial, a liquid biopsy biomarker-driven platform trial for men with metastatic prostate cancer. The trial uses liquid biopsy screening to profile cell-tumor DNA (ctDNA) and select men with detectable ctDNA for randomization to different treatment arms.
ProBio Clinical Trial Team
Department of Medical Epidemiology and Biostatistics, Karolinska Institutet
171 77 Stockholm | Nobels väg 12 A.
+46 852480000
info@probiotrial.org